Marken announced that it has completed all commissioning work for its new operational hub in Feltham, UK. The new location at 648 River Gardens in Feltham is within 4 miles (6 KM) of Heathrow Airport and part of the North Feltham Trading Estate Industrial Center.
The 18.5k sq ft facility is completely occupied by Marken operational personnel and will be one of the company’s flagship facilities joining an expanding network. The facility is equipped with space for product staging, re-icing, automatic scanning, quarantined goods, secure storage for dangerous goods, import and export operations and IT support. It will also have ample office space for the London branch operations which also has responsibility for all clients operating within the UK and Ireland.
“This new facility is in direct response to recent expansion requirements in the UK to support our growing client base”, said CEO, Wes Wheeler. “We have designed this facility to accommodate all of the needs of the life science industry including inbound shipments of clinical samples and outbound shipments of drug product, active pharmaceutical ingredients and patient kits. We have allowed ample room for growth and for expanded services. We are very excited to be upgrading our facilities in the UK.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.